As you can see here, AZ has ended its investigation into the "Bucket of Money" business, in which certain AZ reps were accused of violating AZ's agreement with the OIG not to promote Arimidex by comparing it to Novartis' Femara.
Unfortunately, AZ chose not to follow my advice from April, when I urged the company to be as forthcoming as possible about what its probe found. As a result, many questions remain, and we'll have to wait until the OIG and Congress get done with their investigations before we get answers.
Among those questions:
1. What is Mike Zubillaga's side of the story? This guy has been blamed for everything and yet has remained steadfastly silent. AZ hasn't provided any evidence that he was questioned in its internal probe.
2. How many staff at AZ were disciplined?
3. What was the extent of the discipline they received?
4. Did the probe look at all the allegations raised, including those surrounding the joint promotion with Abraxis' Abraxane and AZ's Faslodex (fulvestrant), or did it just look at the inappropriate Arimidex (anastrozole) comparison allegations?
5. Did any evidence emerge that doctors made any Arimidex prescriptions based on ill-advised comparisons
of Arimidex to Femara?